| scholarly article | Q13442814 |
| P50 | author | Michele Carbone | Q29998675 |
| Harvey I Pass | Q51800337 | ||
| P2093 | author name string | Anil Wali | |
| Alla Ivanova | |||
| Jeffrey Allard | |||
| Michael Harbut | |||
| Naimei Tang | |||
| Sergey Ivanov | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 265-72; discussion 272 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | The Annals of Thoracic Surgery | Q1939819 |
| P1476 | title | Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions | |
| P478 | volume | 85 |
| Q51082110 | A new anti-mesothelin antibody targets selectively the membrane-associated form. |
| Q48367339 | A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels |
| Q34278435 | A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice |
| Q36725369 | Asbestos burden predicts survival in pleural mesothelioma |
| Q33623718 | Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum |
| Q42650225 | Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study |
| Q36199410 | Association of biomarker levels with severity of asbestos-related diseases |
| Q28082088 | Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure |
| Q41593380 | Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q38118298 | Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers |
| Q51206145 | Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. |
| Q35904195 | Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study. |
| Q28238665 | Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions |
| Q41920935 | Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma |
| Q53459612 | Comments on the recently published "Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma". |
| Q35080864 | Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions |
| Q86494895 | Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA |
| Q64227659 | Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis |
| Q37612152 | Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. |
| Q34441092 | Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool |
| Q42863986 | Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs |
| Q46122543 | Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology |
| Q28389535 | Factors that impact susceptibility to fiber-induced health effects |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q26774926 | Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the [...] |
| Q40860144 | Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication |
| Q40809939 | Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q28535472 | Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma |
| Q34760760 | Identification of novel markers for the diagnosis of malignant pleural mesothelioma |
| Q85818463 | Individual predictors of increased serum mesothelin in asbestos-exposed workers |
| Q93048382 | Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives |
| Q21202901 | Malignant mesothelioma |
| Q59274199 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q23918083 | Meeting report: mode(s) of action of asbestos and related mineral fibers |
| Q37139387 | Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q92957225 | Novel single-chain variant of antibody against mesothelin established by phage library |
| Q82235520 | Peritoneal mesothelioma |
| Q42368993 | Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center |
| Q34646018 | Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. |
| Q37975136 | Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy |
| Q39124644 | Prognostication and monitoring of mesothelioma using biomarkers: a systematic review |
| Q37240065 | Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. |
| Q26860736 | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis |
| Q37862752 | Soluble markers for diagnosis of malignant pleural mesothelioma |
| Q36244087 | Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma |
| Q54257584 | Taking measure of personalized medicine: the proteome. |
| Q41376845 | The challenge of prognostic markers in pleural mesothelioma |
| Q35558563 | The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma |
| Q83513912 | [Update in respiratory disease and environmental exposure: an invisible relationship] |
| Q35021181 | fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma |
Search more.